



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

1 July 2010  
EMA/425371/2010  
Patient Health Protection

## Announcement of European Medicines Agency priorities for adverse drug reaction research – 5<sup>th</sup> Call FP7

On 30 November 2009, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted by written procedure its 2011 priorities for drug safety research based on recommendations from the CHMP's Pharmacovigilance Working Party. These priorities were subsequently forwarded to the European Commission for consideration as future topics for the 5<sup>th</sup> Call of the European Commission's 7<sup>th</sup> Framework Programme (FP7).

The Commission has recently published an Orientation Paper with proposed priorities for health research in 2011 for proposals of FP7. The EMA's proposals for adverse drug reaction research are reflected on page 46, under topic 4 "Other actions across the health theme".

The European Medicines Agency now wishes to release complementary information in order to draw the attention of researchers to potential research opportunities (please see links below).

The proposed priorities for health research in 2011 are:

- [Insulin/insulin analogues and development of cancer.](#)
- [Anti-diabetes drugs and cardio/cerebrovascular adverse effects and pancreatitis/pancreatic cancer.](#)
- [Epoetins: Risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular and cancer risk in chronic kidney disease.](#)
- [Asthma treatments \(long and short-acting Beta agonists and anticholinergics\): risk of myocardial ischaemia and long term safety, especially in children.](#)
- [Gadolinium-containing contrast agents: Nephrogenic systemic fibrosis \(NSF\) and long-term effects on the bone and effects following accumulation and delayed release from the bone.](#)

Further information on the FP7 calls and specifically on the proposed priorities for adverse drug reaction research can be found in the Commission's Orientation Paper at:  
[ftp://ftp.cordis.europa.eu/pub/fp7/health/docs/healthres2011-orientation\\_en.pdf](ftp://ftp.cordis.europa.eu/pub/fp7/health/docs/healthres2011-orientation_en.pdf)

